Brief: Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CM
27/03/2025 11:41
March 27 (Reuters) - BridgeBio Pharma Inc BBIO.O: BEYONTTRA™ (ACORAMIDIS), THE FIRST NEAR-COMPLETE TTR STABILIZER (≥90%), APPROVED IN JAPAN TO TREAT ATTR-CM BRIDGEBIO PHARMA- WILL RECEIVE A $30 MILLION MILESTONE PAYMENT UPON APPROVAL IN JAPAN BRIDGEBIO PHARMA INC - WILL GET ROYALTIES IN LOW DOUBLE DIGITS ON SALES OF ACORAMIDIS IN JAPAN Source text: ID:nGNE6VhzHP Further company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels